NCT04414930View on ClinicalTrials.gov

Pharmacologic Augmentation of Targeted Cognitive Training in Schizophrenia

PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

November 9, 2020

Primary Completion Date

September 30, 2024

Study Completion Date

September 30, 2024

Conditions
SchizophreniaSchizoaffective Disorder
Interventions
DRUG

d-amphetamine

Subjects complete 30 sessions of Targeted Cognitive Training (2-3 times per week), and receive amphetamine 5 mg po 1 hour prior to each training.

DRUG

Placebo

Subjects complete 30 sessions of Targeted Cognitive Training (2-3 times per week), and receive placebo po 1 hour prior to each training.

Trial Locations (1)

92103

Clinical Teaching Facility (CTF-B102) at UCSD Medical Center, San Diego

All Listed Sponsors
lead

University of California, San Diego

OTHER

NCT04414930 - Pharmacologic Augmentation of Targeted Cognitive Training in Schizophrenia | Biotech Hunter | Biotech Hunter